Volume 11 Issue 5, November 2017

C-Bridge Capital specializes in the growing Chinese health care market and is using its expertize to identify emerging industry leaders and bring global innovation into China.

Building on its history of successful collaborations, Sanofi Pasteur, the vaccines Global Business Unit of Sanofi, is seeking partners with a common drive for excellence and pursuit of innovation.

By using a tissue-specific hormone inhibitor to rebalance local estrogen metabolism, Forendo Pharma could provide long-term treatment to millions of women suffering from endometriosis.

Applying its TIL-based therapy, Iovance Biotherapeutics is expanding TIL numbers in patients to target solid tumors.

Despite recent clinical trial failures, there is a robust dealmaking and funding environment for companies tackling diseases of the central nervous system, indicating that eventual success is expected.

Indivior is investing in research and development to pioneer life-transforming treatments in addiction medicine, and in partnerships worldwide to realize its vision that all patients will have access to quality treatment for the chronic relapsing conditions and co-occurring disorders of addiction.

The first ondansetron orally dissolving film (ODF) has been approved in Japan, validating TAHO’s platform technology from prototype to commercial product.

Probiodrug is using a multi-pronged approach to reduce brain levels of pyroglutamate–amyloid-β peptides; results from the SAPHIR IIa trial for the company’s lead candidate PQ912 reveal positive early efficacy data that are highly attractive for further development.

Attracting both investors and big pharma, Mission Therapeutics is targeting a range of unmet medical needs, including Parkinson’s disease, with its unique deubiquitylating enzyme (DUB) platform.

BioAxone is developing a suite of game-changing treatments for spinal cord injury, neurovascular diseases, and eye disorders by targeting Rho/Rho kinase signaling pathways involved in a variety of pathological processes.

ABL Bio’s first-in-class bispecific antibodies for Parkinson’s disease combine unprecedented blood–brain barrier penetration with a robust mechanism of action for improved therapeutic efficacy. The company is looking for partners to codevelop or out-license bispecific antibodies able to penetrate the blood–brain barrier.

Abide Therapeutics’ lead product ABX-1431, which is about to reach phase 2 trials, is the first drug candidate to emerge from Abide’s unique platform for generating first-in-class serine-hydrolase-targeted therapeutics.

Through an innovative approach to both science and business, Ovid Therapeutics is developing impactful medicines for people with rare neurological disorders.

With several products in advanced clinical stages, such as oral CGRP-receptor antagonists and glutamate modulators, Biohaven is welcoming collaborations on these programs and broadening its pipeline further.

With a pioneering gene therapy now on the brink of approval, this feature highlights some of the key deals and news in the field in the past five years.

Aposense is powering drug delivery by means of a recently discovered electrostatic field residing in the phospholipid membrane.

Brainstorm Cell Therapeutics is looking for financial and corporate partners to help complete the development and launch of revolutionary neurodegenerative disease treatments.

BrightPath, formerly known as GreenPeptide, is moving beyond peptides to push the boundaries of cancer immunotherapy toward more personalized treatments.

Isoplexis helps researchers target the right therapies early to the highest-urgency cancer patients.

Clinical-stage biopharmaceutical company Fate Therapeutics is creating first-in-class (re)programmed cellular immunotherapies for cancer and immune disorders. Preclinical and clinical development of the company’s product pipeline is driven by a determined pursuit of a new cell therapy paradigm and an expanding array of strategic partnerships to support its innovative mission